Related Experiment Video
Updated: Dec 9, 2025
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite
Hyae Min Jeon1, Jae Seok Lee2, Soo Hee Kim1
1Pathology Center, Seegene Medical Foundation, Seoul, Republic of Korea.
Background:
Developing personalized strategies for cancer has shown good efficacies.
Methods:
We assessed the molecular targets programmed death ligand 1 (PD-L1), microsatellite instability (MSI), and PIK3CA. Seventy-four patients with liposarcomas who underwent curative resection were assessed for PD-L1 expression in the tumor and tumor-infiltrating lymphocytes (TILs), mismatch repair proteins (MLH1, PMS2, MSH2, and MSH6) by immunohistochemistry, MSI using polymerase chain reaction, and PIK3CA mutation/amplification using pyrosequencing and fluorescence in situ hybridization.
Results:
Seventeen (23%) cases were TIL+ (≥1 + expression) and associated with longer 5-year overall survival than those with TIL- tumors (84.4 vs. 60.8%, p = 0.007). Six (35.3%) PD-L1+ tumors were detected only in TIL+ cases, with none detected in tumor cells. Two well-differentiated liposarcomas showed MSI, one low and one high with concurrent loss of MLH1, MSH6, and PMS2. PIK3CA mutation was detected in 7 (9.5%) [exon 9 (n = 4) and exon 20 (n = 3)] and only 1 Q546K mutation was a PD-L1+ tumor. PIK3CA copy number gain was detected in 18 (24.4%) and was associated with TIL+ tumors (p = 0.045).
Conclusions:
Our comprehensive immuno-molecular panel suggests that liposarcoma should be categorized based on the molecular genomic subtype for precision medicine.
Insights
Personalized cancer strategies improve outcomes. In liposarcoma, tumor-infiltrating lymphocytes (TILs) and PD-L1 expression correlate with survival, suggesting molecular subtyping for precision medicine.
Area of Science:
- Oncology
- Genomics
- Immunology
Background:
- Personalized cancer treatment strategies demonstrate significant efficacy.
- Liposarcoma, a complex soft tissue sarcoma, requires refined therapeutic approaches.
Purpose of the Study:
- To investigate the role of programmed death ligand 1 (PD-L1), microsatellite instability (MSI), and PIK3CA in liposarcoma.
- To correlate these molecular markers with clinical outcomes and tumor-infiltrating lymphocytes (TILs).
Main Methods:
- Assessed PD-L1 expression in tumor and TILs via immunohistochemistry in 74 liposarcoma patients.
- Analyzed MSI using PCR and PIK3CA mutations/amplification using pyrosequencing and FISH.
- Evaluated mismatch repair proteins (MLH1, PMS2, MSH2, MSH6).
Main Results:
- Seventeen percent of cases were TIL+ (tumor-infiltrating lymphocytes positive), associated with improved 5-year overall survival (84.4% vs. 60.8%).
- PD-L1 positivity was observed in 35.3% of TIL+ cases, exclusively within TILs.
- PIK3CA copy number gain occurred in 24.4% and was linked to TIL+ status (p=0.045).
Conclusions:
- Immuno-molecular profiling of liposarcoma is crucial for precision medicine.
- Categorizing liposarcoma by molecular genomic subtype may guide targeted therapies.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
